GLP-1-mediated gene therapy approaches for diabetes treatment

Mukerrem Hale Tasyurek, Hasan Ali Altunbas, Halit Canatan, Thomas S. Griffith, Salih Sanlioglu

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


Glucagon-like peptide (GLP)-1 is an incretin hormone with several antidiabetic functions including stimulation of glucose-dependent insulin secretion, increase in insulin gene expression and beta-cell survival. Despite the initial technical difficulties and profound inefficiency of direct gene transfer into the pancreas that seriously restricted in vivo gene transfer experiments with GLP-1, recent exploitation of various routes of gene delivery and alternative means of gene transfer has permitted the detailed assessment of the therapeutic efficacy of GLP-1 in animal models of type 2 diabetes (T2DM). As a result, many clinical benefits of GLP-1 peptide/analogues observed in clinical trials involving induction of glucose tolerance, reduction of hyperglycaemia, suppression of appetite and food intake linked to weight loss have been replicated in animal models using gene therapy. Furthermore, GLP-1-centered gene therapy not only improved insulin sensitivity, but also reduced abdominal and/or hepatic fat associated with obesity-induced T2DM with drastic alterations in adipokine profiles in treated subjects. Thus, a comprehensive assessment of recent GLP-1-mediated gene therapy approaches with detailed analysis of current hurdles and resolutions, is discussed.

Original languageEnglish (US)
JournalExpert reviews in molecular medicine
StatePublished - Mar 26 2014

Bibliographical note

Publisher Copyright:
© 2014 Cambridge University Press.


Dive into the research topics of 'GLP-1-mediated gene therapy approaches for diabetes treatment'. Together they form a unique fingerprint.

Cite this